Quotient Sciences

“We have built considerable expertise in GLP-1 drug development through our oral peptide programs”

This week, Speak Pharma interviews Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences, a drug development and man...

“Our Translational Pharmaceutics platform shortens drug development timelines by over 12 months”

This week, SpeakPharma interviews John McDermott, Vice President of Scientific Consulting at Quotient Sciences, a drug develop...

“Quotient Sciences’ integrated approach to drug development accelerates molecules to IND & beyond”

This week, SpeakPharma interviews Eleanor Row, Executive Director of Commercial at Quotient Sciences, a global drug developmen...

“For orphan drugs, we identify a patient-ready formulation in less than half the time.”

This week, SpeakPharma interviews Dr. Peter Scholes, Chief Scientific Officer, Quotient Sciences, who talks about orphan drugs...